Nagio Takigawa

16.1k total citations
304 papers, 5.2k citations indexed

About

Nagio Takigawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Nagio Takigawa has authored 304 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Pulmonary and Respiratory Medicine, 185 papers in Oncology and 76 papers in Molecular Biology. Recurrent topics in Nagio Takigawa's work include Lung Cancer Treatments and Mutations (147 papers), Lung Cancer Research Studies (100 papers) and Lung Cancer Diagnosis and Treatment (50 papers). Nagio Takigawa is often cited by papers focused on Lung Cancer Treatments and Mutations (147 papers), Lung Cancer Research Studies (100 papers) and Lung Cancer Diagnosis and Treatment (50 papers). Nagio Takigawa collaborates with scholars based in Japan, United States and United Kingdom. Nagio Takigawa's co-authors include Katsuyuki Kiura, Mitsune Tanimoto, Katsuyuki Hotta, Masahiro Tabata, Yoshihiko Segawa, Eiki Ichihara, Hiroshi Ueoka, Nobuaki Ochi, Daijiro Harada and Yoshiro Fujiwara and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nagio Takigawa

292 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nagio Takigawa Japan 41 2.9k 2.9k 1.9k 749 432 304 5.2k
Mark Vincent Canada 38 3.7k 1.3× 3.8k 1.3× 1.5k 0.8× 723 1.0× 420 1.0× 171 6.5k
Hiroshi Nokihara Japan 40 3.3k 1.1× 3.9k 1.3× 1.7k 0.9× 935 1.2× 656 1.5× 237 5.9k
Jyoti D. Patel United States 38 3.4k 1.2× 3.9k 1.3× 1.4k 0.7× 832 1.1× 375 0.9× 230 6.1k
James Stevenson United States 38 2.8k 1.0× 3.5k 1.2× 1.2k 0.6× 546 0.7× 378 0.9× 137 5.9k
Masahiro Tabata Japan 35 2.9k 1.0× 2.9k 1.0× 1.3k 0.7× 606 0.8× 465 1.1× 225 4.5k
Siow Ming Lee United Kingdom 38 2.0k 0.7× 2.4k 0.8× 1.6k 0.8× 547 0.7× 695 1.6× 171 4.9k
Petr Zatloukal Czechia 33 3.4k 1.2× 3.7k 1.3× 1.6k 0.8× 603 0.8× 410 0.9× 87 5.7k
Seiji Niho Japan 37 3.0k 1.0× 3.2k 1.1× 1.1k 0.6× 547 0.7× 894 2.1× 213 5.1k
Anne S. Tsao United States 42 4.3k 1.5× 2.6k 0.9× 1.4k 0.7× 724 1.0× 295 0.7× 217 6.7k
Dolores Isla Spain 30 3.1k 1.1× 3.1k 1.1× 1.5k 0.8× 888 1.2× 210 0.5× 202 5.1k

Countries citing papers authored by Nagio Takigawa

Since Specialization
Citations

This map shows the geographic impact of Nagio Takigawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nagio Takigawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nagio Takigawa more than expected).

Fields of papers citing papers by Nagio Takigawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nagio Takigawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nagio Takigawa. The network helps show where Nagio Takigawa may publish in the future.

Co-authorship network of co-authors of Nagio Takigawa

This figure shows the co-authorship network connecting the top 25 collaborators of Nagio Takigawa. A scholar is included among the top collaborators of Nagio Takigawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nagio Takigawa. Nagio Takigawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Urano, Takashi, Etsuko Yokota, Takuro Yukawa, et al.. (2025). Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability. Human Cell. 38(3). 72–72. 1 indexed citations
2.
Yamane, Hiromichi, et al.. (2024). Four Cases with FUS/CHOP Fusion Gene Products Positive Myxoid Liposarcoma Responding Effectively to Trabectedin Monotherapy. OncoTargets and Therapy. Volume 17. 1059–1067.
3.
Sunada, Yoshihide, et al.. (2024). A case of primary duodenal Brunner's gland hamartoma that gradually underwent morphological changes over a period of 10 years. SHILAP Revista de lepidopterología. 5(1). e70028–e70028. 1 indexed citations
4.
Yamane, Hiromichi, et al.. (2023). Clinical Features of Patients With Hematological Malignancies Treated at the Palliative Care Unit. SHILAP Revista de lepidopterología. 4(1). 278–287. 3 indexed citations
5.
Miyake, Noriko, Nobuaki Ochi, Hiromichi Yamane, et al.. (2021). Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. Experimental Cell Research. 409(2). 112940–112940. 4 indexed citations
6.
Isozaki, Hideko, Eiki Ichihara, Nagio Takigawa, et al.. (2016). Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research. 76(6). 1506–1516. 109 indexed citations
7.
Takigawa, Nagio. (2016). MET-inhibitors meet MET mutations in lung cancer. Translational Cancer Research. 5(6). 1 indexed citations
8.
Yamane, Hiromichi, Hideko Isozaki, Masami Takeyama, et al.. (2015). Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.. Europe PMC (PubMed Central). 5(4). 1553–7. 27 indexed citations
9.
Saito, Ken, Nagio Takigawa, Naoko Ohtani, et al.. (2013). Antitumor Impact of p14ARF on Gefitinib-Resistant Non–Small Cell Lung Cancers. Molecular Cancer Therapeutics. 12(8). 1616–1628. 12 indexed citations
10.
Shien, Kazuhiko, Shinichi Toyooka, Hiromasa Yamamoto, et al.. (2013). Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells. Cancer Research. 73(10). 3051–3061. 223 indexed citations
11.
Yamane, Hiromichi, et al.. (2013). Fatal interstitial pneumonia caused by panitumumab-containing chemotherapy: a case report. 39(1). 49–53. 2 indexed citations
12.
Hayakawa, Hiromi, Eiki Ichihara, Kadoaki Ohashi, et al.. (2013). Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model. Cancer Science. 104(11). 1440–1446. 29 indexed citations
13.
Minami, Daisuke, Nagio Takigawa, Minoru Takata, et al.. (2012). Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN -Deficient Lung Cancer Cells. Molecular Cancer Research. 11(2). 140–148. 50 indexed citations
14.
Rai, Kammei, Nagio Takigawa, Sachio Ito, et al.. (2011). Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells. Molecular Cancer Therapeutics. 10(9). 1720–1727. 110 indexed citations
15.
Takigawa, Nagio, Yoshihiko Segawa, Toshio Kubo, et al.. (2011). STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer. 75(1). 24–29. 17 indexed citations
16.
Ohashi, Kadoaki, Nagio Takigawa, Eiki Ichihara, et al.. (2009). Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Research. 69(17). 7088–7095. 17 indexed citations
17.
Kuyama, Shoichi, Katsuyuki Hotta, Masahiro Tabata, et al.. (2008). Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(5). 477–482. 45 indexed citations
18.
Kubo, Takafumi, Hiromasa Yamamoto, William W. Lockwood, et al.. (2008). MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer. 124(8). 1778–1784. 117 indexed citations
19.
Ichihara, Eiki, Kadoaki Ohashi, Nagio Takigawa, et al.. (2008). Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment. Cancer Research. 68. 678–678.
20.
Takigawa, Nagio, Mikiko Ida, Yoshihiko Segawa, et al.. (2004). Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.. PubMed. 23(6D). 5069–73. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Vincent Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Jyoti D. Patel Breakdown of academic impact, for papers by James Stevenson Breakdown of academic impact, for papers by Masahiro Tabata Breakdown of academic impact, for papers by Siow Ming Lee Breakdown of academic impact, for papers by Petr Zatloukal Breakdown of academic impact, for papers by Seiji Niho Breakdown of academic impact, for papers by Anne S. Tsao Breakdown of academic impact, for papers by Dolores Isla
Rankless by CCL
2026